{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T07:17:23Z","timestamp":1794727043844,"version":"4.9.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":942,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>\n                                 <jats:bold>The associations between diabetes, smoking, obesity, and intrahepatic cholangiocarcinoma (ICC) risk remain inconclusive. Metformin is purportedly associated with a reduced risk for various cancers. This case-control study evaluated risk factors for ICC and explored the effects of metformin on ICC risk in a clinic\/hospital-based cohort. ICC patients observed at the Mayo Clinic (Rochester, MN) between January 2000 and May 2010 were identified. Age, sex, ethnicity, and residential area-matched controls were selected from among Mayo Clinic Biobank participants. The associations between potential factors and ICC risk were determined. Six hundred and twelve cases and 594 controls were identified. Factors associated with increased ICC risk included biliary tract diseases (adjusted odds ratio [AOR]: 81.8; 95% confidence interval [CI]: 11.2-598.8;<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>&lt; 0.001), cirrhosis (AOR, 8.0; 95% CI: 1.8-36.5;<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>= 0.007), diabetes (AOR, 3.6; 95% CI: 2.3-5.5;<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>&lt; 0.001), and smoking (AOR, 1.6; 95% CI: 1.3-2.1;<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>&lt; 0.001). Compared to diabetic patients not treated with metformin, the odds ratio (OR) for ICC for diabetic patients treated with metformin was significantly decreased (OR, 0.4; 95% CI: 0.2-0.9;<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>= 0.04). Obesity and metabolic syndrome were not associated with ICC.<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>\n                                 <jats:bold>This study confirmed diabetes and smoking as independent risk factors for ICC. A novel finding was that treatment with metformin was significantly associated with a 60% reduction in ICC risk in diabetic patients.<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.26092","type":"journal-article","created":{"date-parts":[[2012,10,11]],"date-time":"2012-10-11T13:27:11Z","timestamp":1349962031000},"page":"648-655","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":120,"title":["Risk Factors for Intrahepatic Cholangiocarcinoma: Association Between Metformin Use and Reduced Cancer Risk"],"prefix":"10.1097","volume":"57","author":[{"given":"Roongruedee","family":"Chaiteerakij","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Dong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S.","family":"Harmsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth W.","family":"Slettedahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa A.","family":"Mettler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary S.","family":"Fredericksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray W.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Gores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosebud O.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry M.","family":"Therneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis R.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-24-20241201","doi-asserted-by":"crossref","first-page":"13531357","DOI":"10.1053\/jhep.2001.25087","article-title":"Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States.","volume":"33","author":"Patel","year":"2001","journal-title":"HEPATOLOGY"},{"key":"R2-24-20241201","doi-asserted-by":"crossref","first-page":"472477","DOI":"10.1016\/j.jhep.2003.11.030","article-title":"Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?","volume":"40","author":"Shaib","year":"2004","journal-title":"J Hepatol"},{"key":"R3-24-20241201","first-page":"12561262","article-title":"Biliary tract cancers in Olmsted County, Minnesota, 19762008.","volume":"107","author":"Yang","year":"2012","journal-title":"Am J Gastroenterology"},{"key":"R4-24-20241201","doi-asserted-by":"crossref","first-page":"17161720","DOI":"10.1111\/j.1572-0241.2008.01796.x","article-title":"Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a casecontrol study.","volume":"103","author":"Lee","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R5-24-20241201","doi-asserted-by":"crossref","first-page":"620626","DOI":"10.1053\/j.gastro.2004.12.048","article-title":"Risk factors of intrahepatic cholangiocarcinoma in the United States: a casecontrol study.","volume":"128","author":"Shaib","year":"2005","journal-title":"Gastroenterology"},{"key":"R6-24-20241201","doi-asserted-by":"crossref","first-page":"10161021","DOI":"10.1111\/j.1572-0241.2007.01104.x","article-title":"Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospitalbased casecontrol study.","volume":"102","author":"Shaib","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R7-24-20241201","doi-asserted-by":"crossref","first-page":"12211228","DOI":"10.1016\/j.cgh.2007.05.020","article-title":"Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a populationbased casecontrol study.","volume":"5","author":"Welzel","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R8-24-20241201","doi-asserted-by":"crossref","first-page":"178180","DOI":"10.1038\/sj.bjc.6604765","article-title":"The antecedents of biliary cancer: a primary care casecontrol study in the United Kingdom.","volume":"100","author":"Grainge","year":"2009","journal-title":"Br J Cancer"},{"key":"R9-24-20241201","doi-asserted-by":"crossref","first-page":"632635","DOI":"10.3748\/wjg.14.632","article-title":"Risk factors for intrahepatic cholangiocarcinoma: a casecontrol study in China.","volume":"14","author":"Zhou","year":"2008","journal-title":"World J Gastroenterol"},{"key":"R10-24-20241201","doi-asserted-by":"crossref","first-page":"592595","DOI":"10.1111\/j.1349-7006.2004.tb02492.x","article-title":"Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma.","volume":"95","author":"Yamamoto","year":"2004","journal-title":"Cancer Sci"},{"key":"R11-24-20241201","doi-asserted-by":"crossref","first-page":"323328","DOI":"10.1002\/ijc.2910480302","article-title":"Liver cancer in Thailand. I. A casecontrol study of cholangiocarcinoma.","volume":"48","author":"Parkin","year":"1991","journal-title":"Int J Cancer"},{"key":"R12-24-20241201","doi-asserted-by":"crossref","first-page":"959964","DOI":"10.1023\/A:1013747228572","article-title":"Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a casecontrol study in Italy.","volume":"12","author":"Donato","year":"2001","journal-title":"Cancer Causes Control"},{"key":"R13-24-20241201","doi-asserted-by":"crossref","first-page":"333340","DOI":"10.1111\/j.1751-2980.2010.00469.x","article-title":"Epidemiology of the metabolic syndrome in the USA.","volume":"12","author":"McCullough","year":"2011","journal-title":"J Dig Dis"},{"key":"R14-24-20241201","doi-asserted-by":"crossref","first-page":"463471","DOI":"10.1002\/hep.24397","article-title":"Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEERMedicare database.","volume":"54","author":"Welzel","year":"2011","journal-title":"HEPATOLOGY"},{"key":"R15-24-20241201","doi-asserted-by":"crossref","first-page":"750758","DOI":"10.1111\/j.1478-3231.2010.02223.x","article-title":"Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease.","volume":"30","author":"Donadon","year":"2010","journal-title":"Liver Int"},{"key":"R16-24-20241201","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-2407-11-20","article-title":"Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals.","volume":"11","author":"Lee","year":"2011","journal-title":"BMC cancer"},{"key":"R17-24-20241201","doi-asserted-by":"crossref","first-page":"482488","DOI":"10.1053\/j.gastro.2009.04.013","article-title":"Antidiabetic therapies affect risk of pancreatic cancer.","volume":"137","author":"Li","year":"2009","journal-title":"Gastroenterology"},{"key":"R18-24-20241201","doi-asserted-by":"crossref","first-page":"19381946","DOI":"10.1002\/cncr.24982","article-title":"Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma.","volume":"116","author":"Hassan","year":"2010","journal-title":"Cancer"},{"key":"R19-24-20241201","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1038\/ajg.2011.384","article-title":"Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with antidiabetic therapy: a populationbased cohort study.","volume":"107","author":"Lai","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"R20-24-20241201","doi-asserted-by":"crossref","first-page":"752759","DOI":"10.1002\/ijc.26421","article-title":"The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus.","volume":"131","author":"Lee","year":"2012","journal-title":"Int J Cancer"},{"key":"R21-24-20241201","first-page":"16011608","article-title":"Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes.","volume":"136","author":"ElSerag","year":"2009","journal-title":"Gastroenterology"},{"key":"R22-24-20241201","first-page":"894898","article-title":"Statin use and the risk of liver cancer: a populationbased case-control study.","volume":"106","author":"Chiu","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"R23-24-20241201","first-page":"27352752","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart AssociationNational Heart, Lung, and Blood Institute Scientific Statement.","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"R24-24-20241201","doi-asserted-by":"crossref","first-page":"159174","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data.","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"key":"R26-24-20241201","doi-asserted-by":"crossref","first-page":"16741685","DOI":"10.2337\/dc10-0666","article-title":"Diabetes and cancer: a consensus report.","volume":"33","author":"Giovannucci","year":"2010","journal-title":"Diabetes Care"},{"key":"R27-24-20241201","doi-asserted-by":"crossref","first-page":"877888","DOI":"10.2353\/ajpath.2006.050464","article-title":"Estrogens and insulinlike growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma.","volume":"169","author":"Alvaro","year":"2006","journal-title":"Am J Pathol"},{"key":"R28-24-20241201","doi-asserted-by":"crossref","first-page":"448458","DOI":"10.1038\/nrgastro.2010.100","article-title":"Hepatocellular carcinoma: a global view.","volume":"7","author":"Yang","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R29-24-20241201","doi-asserted-by":"crossref","first-page":"1026910273","DOI":"10.1158\/0008-5472.CAN-06-1500","article-title":"Metformin is an AMP kinasedependent growth inhibitor for breast cancer cells.","volume":"66","author":"Zakikhani","year":"2006","journal-title":"Cancer Res"},{"key":"R30-24-20241201","first-page":"35763586","article-title":"The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.","volume":"27","author":"Ben Sahra","year":"2008","journal-title":"Oncogene"},{"issue":"Suppl 1","key":"R31-24-20241201","first-page":"S11S61","article-title":"Standards of medical care in diabetes2011.","volume":"34","year":"2011","journal-title":"Diabetes Care"},{"key":"R32-24-20241201","doi-asserted-by":"crossref","first-page":"177194","DOI":"10.1592\/phco.30.2.177","article-title":"A clinical review of statins and cancer: helpful or harmful?","volume":"30","author":"Gonyeau","year":"2010","journal-title":"Pharmacotherapy"},{"key":"R33-24-20241201","doi-asserted-by":"crossref","first-page":"274285","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: the epidemiology and natural history of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults.","volume":"34","author":"Vernon","year":"2011","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.26092","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201302000-00024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T14:05:29Z","timestamp":1733061929000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201302000-00024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.26092","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}